Compositions and methods for mucosal delivery of agents are provided. The emulsion compositions are intended for administration to a mucosal surface, such as oral, gastrointestinal and nasal mucosa. The emulsion compositions provided contain one or more mucoadhesive proteins and an agent to be delivered. Methods for delivery of agents using the compositions provided herein are also provided.

The disclosure discloses Lactococcus lactis subsp. lactis CCFM1018 and application thereof in preparation of food and medicine for excreting a plasticizer, and belongs to the technical field of microorganisms. The Lactococcus lactis subsp. lactis CCFM1018 not only is significantly better than the intestinal resident bacteria Escherichia coli and Enterococcus faecalis in terms of the effect of promoting the excretion of DEHP and MEHP, but also is better than the commercial strain Lactobacillus rhamnosus LGG. Therefore, the Lactococcus lactis subsp. lactis CCFM1018 of the disclosure can be used as an effective means to prevent and alleviate body damage caused by DEHP and MEHP, and does not have toxic or side effects of drugs. Lactococcus lactis subsp. lactis CCFM1018 can be used to prepare pharmaceutical compositions and fermented food for alleviating and preventing the toxicity of DEHP and metabolites thereof, and has a very broad application prospect.

A method of treating or preventing overgrowth by pathogenic bacteria in a subject deficient in butyrate and/or butyrate-producing bacteria in their gut microbiota by administering a therapeutically effective amount of a butyrate-producing bacteria to the subject is described. A prebiotic can be included with the butyrate-producing bacteria. Overgrowth by pathogenic bacteria is commonly caused by antibiotic administration.

The present disclosure relates to a novel Lactobacillus plantarum CJLP475 strain having acid-resistance, bile-resistance and an immune-enhancing activity, and a composition including the same.

The present invention relates to a Lactobacillus rhamnosus LM1019 strain (accession number KCCM12308P), and a composition for preventing and treating obesity or diabetes mellitus, comprising the same. Specifically, the Lactobacillus rhamnosus LM1019 strain of the present invention reduces fat cells, neutral fats, subcutaneous fats, and cholesterol, thus having an effect of preventing and treating obesity, and also reduces the blood glucose concentration and the blood insulin concentration, thereby inhibiting insulin resistance and thus having an effect of preventing and treating diabetes mellitus.

The invention relates to a process for the preparation of dry lyophilized powdered formulations of probiotic bacteria for monogastric animal (for example poultry birds) using a combination of different polymers through the process of encapsulation. The resulting lyophilized powders of probiotic bacteria are having increased viability during animal feed processing, storage and upon transfer to the monogastric animal's digestive system.

Provided herein are polynucleic acids and expression vectors for the expression and secretion of angiotensin peptide fragments (e.g., angiotensin-(1-7)) in probiotic bacteria. Provided herein are also probiotic compositions that enable efficient, cost-effective and patient friendly oral therapeutics for treating diverse pathological conditions that involve the renin-angiotensin system (RAS), e.g., pulmonary hypertension, diabetes, diabetic complications, cardiovascular diseases, and ocular inflammatory and neurodegenerative diseases.

The present disclosure provides compositions and methods for improving disease resistance, increasing weight gain, and reducing the incidence and/or severity of clinical signs of infection. The composition generally comprises one or more microorganisms that is administered to an animal in need thereof. Preferred infections that can be combated with the compositions and methods of this disclosure are respiratory infections including PRRSV and PCV2.

The invention relates to using a class of microbial species that can contribute to robust recovery of the microbiome after antibiotic usage. In particular, the inventors of this invention have identified 21 bacterial species exhibiting robust association with ecological recovery post antibiotic therapy. As such, in an aspect of the invention, there is provided a use of composition comprising at least one of or any combination of microorganisms selected from the group consisting of: Bacteroides thetaiotaomicron, Bifidobacterium adolescentis, Alistipes putredinis, Alistipes shahii, Bacteroides caccae, Bacteroides coprocola, Bacteroides eggerthii, Bacteroides intestinalis, Bacteroides stercoris, Bacteroides uniformis, Bifidobacterium bifidum, Bifidobacterium longum, Coprococcus catus, Desulfovibrio piger, Faecalibacterium prausnitzii, Parabacteroides distasonis, Parabacteroides johnsonii, Roseburia inulinivorans, Ruminococcus bromii, Ruminococcus torques, and Subdoligranulum variabile for treating or decreasing gut microbiome dysbiosis induced by a prior antibiotic treatment.

The invention provides probiotic bacteria and lysates thereof for use in methods of medical and cosmetic treatment. Use in the treatment of infections, including skin infections and methods involving regeneration or repair of the skin barrier are contemplated.